Elanco Animal Health (NYSE:ELAN) Stock Price Expected to Rise, UBS Group Analyst Says

Elanco Animal Health (NYSE:ELAN) had its price target hoisted by equities researchers at UBS Group from $25.00 to $27.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. UBS Group’s target price points to a potential upside of 25.61% from the company’s current price.

Several other research analysts have also weighed in on the company. Piper Sandler increased their price objective on Elanco Animal Health from $12.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, August 11th. Leerink Partnrs upgraded Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 17th. Weiss Ratings reissued a “hold (c-)” rating on shares of Elanco Animal Health in a research report on Wednesday, October 8th. Stifel Nicolaus upped their target price on shares of Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Finally, Leerink Partners raised shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 target price for the company in a research note on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Elanco Animal Health presently has an average rating of “Moderate Buy” and an average price target of $20.29.

Elanco Animal Health Price Performance

Elanco Animal Health stock opened at $21.50 on Thursday. The company has a current ratio of 2.40, a quick ratio of 1.40 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average price of $20.17 and a 200 day moving average price of $16.16. Elanco Animal Health has a 12-month low of $8.02 and a 12-month high of $22.98. The stock has a market cap of $10.68 billion, a P/E ratio of 358.31, a PEG ratio of 3.24 and a beta of 1.71.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The business’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.13 EPS. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS. Sell-side analysts anticipate that Elanco Animal Health will post 0.91 earnings per share for the current year.

Hedge Funds Weigh In On Elanco Animal Health

Several institutional investors have recently bought and sold shares of ELAN. AlphaQuest LLC lifted its position in shares of Elanco Animal Health by 13.7% during the third quarter. AlphaQuest LLC now owns 5,953 shares of the company’s stock worth $120,000 after purchasing an additional 718 shares in the last quarter. Jones Financial Companies Lllp grew its holdings in shares of Elanco Animal Health by 15.2% in the third quarter. Jones Financial Companies Lllp now owns 6,065 shares of the company’s stock valued at $119,000 after purchasing an additional 798 shares in the last quarter. MTM Investment Management LLC increased its stake in Elanco Animal Health by 5.5% during the 2nd quarter. MTM Investment Management LLC now owns 15,268 shares of the company’s stock worth $218,000 after buying an additional 800 shares during the period. HighTower Advisors LLC lifted its holdings in Elanco Animal Health by 7.0% during the 1st quarter. HighTower Advisors LLC now owns 12,445 shares of the company’s stock worth $131,000 after buying an additional 810 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. boosted its position in Elanco Animal Health by 80.3% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after buying an additional 900 shares during the period. 97.48% of the stock is owned by institutional investors and hedge funds.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.